Division of Immunopathology, Department of Pathophysiology, Center for Physiology and Pathophysiology, Medical University of Vienna, Vienna, Austria.
Allergy. 2010 Mar;65(3):296-303. doi: 10.1111/j.1398-9995.2009.02202.x. Epub 2009 Oct 12.
During the last decade allergen molecules from several allergen sources have been produced by recombinant DNA technology. The aim of this study was to investigate whether IgE reactivity to recombinant pollen allergens with broad and narrow cross-reactivity is associated with clinical phenotypes of allergic sensitization.
Serum IgE reactivity to a panel of six recombinant birch and grass pollen allergens was measured by ELISA in pollen sensitized patients from Central Europe to define groups of patients with exclusive IgE reactivity to rBet v 1, with exclusive reactivity to major grass pollen allergens (rPhl p 1, rPhl p 2, rPhl p 5) and with IgE reactivity to cross-reactive pollen allergens (rBet v 2, rPhl p 7). Patients' clinical phenotypes were recorded. IgE responses to tree, grass and weed pollen as well as plant food extracts were evaluated in vitro by CAP-FEIA and clinical sensitivities were confirmed in vivo by skin prick testing.
IgE reactivity to the recombinant major birch pollen allergen, rBet v 1, was associated with sensitization to pollen from birch, taxonomically related trees and to certain plant-derived food. Reactivity to the recombinant timothy grass pollen allergens, rPhl p 1, rPhl p 2, rPhl p 5, indicated sensitization to pollen from grasses. Patients reacting with the highly cross-reactive allergen rPhl p 7 were polysensitized to pollen from unrelated trees, grasses and weeds and rBet v 2-positive patients were polysensitized to pollen and plant-derived food from unrelated plants.
IgE reactivity to recombinant marker allergens is associated with clinical phenotypes of allergic sensitization and may be useful for the selection of treatment strategies.
在过去的十年中，几种过敏原来源的过敏原分子已通过重组 DNA 技术生产。本研究的目的是调查对具有广泛和窄交叉反应性的重组花粉过敏原的 IgE 反应性是否与过敏致敏的临床表型相关。
通过 ELISA 测量来自中欧花粉致敏患者的一组六个重组桦树和草花粉过敏原的血清 IgE 反应性，以定义对 rBet v 1 具有特异性 IgE 反应性的患者组、对主要草花粉过敏原（rPhl p 1、rPhl p 2、rPhl p 5）具有特异性反应性的患者组和对交叉反应性花粉过敏原（rBet v 2、rPhl p 7）具有 IgE 反应性的患者组。记录患者的临床表型。通过 CAP-FEIA 体外评估对树木、草和杂草花粉以及植物食物提取物的 IgE 反应，通过皮肤点刺试验体内确认临床敏感性。
对重组主要桦树花粉过敏原 rBet v 1 的 IgE 反应性与对桦树、分类上相关的树木和某些植物源性食物的花粉致敏有关。对重组豚草花粉过敏原 rPhl p 1、rPhl p 2、rPhl p 5 的反应性表明对草花粉致敏。对高度交叉反应性过敏原 rPhl p 7 反应的患者对来自无关树木、草和杂草的花粉和 rBet v 2 阳性患者对来自无关植物的花粉和植物源性食物呈多敏性。
对重组标记过敏原的 IgE 反应性与过敏致敏的临床表型相关，可用于选择治疗策略。
